Peptency Academy · Guide
Regulatory status of peptide patches in the US, EU and UK
How are peptide patches classified and regulated in the US, the EU and the UK?
Abstract, first sentences: regulatory science for this emerging product form is immature and explicit guidance is limited.1 J Control Release 2025
Regulatory content shown for: EU and UK.
Known, not known, contested
Known
- The same paper identifies more than twenty critical quality attributes for the product form and ranks which of them need bespoke tests. Source sentence
Abstract, final sentences: a prioritisation exercise identifies the most pertinent attributes.
1 J Control Release 2025
Not known
- The same search method found no controlled delivery study of a patch without microneedles carrying GHK-Cu, BPC-157 or semaglutide. Source sentence
Query run on 11 November 2026; no controlled study of a flat patch delivering these peptides in the results.
2 PubMed search for transdermal patch without microneedles, 11 November 2026
Contested
Nothing listed yet.
European Union: the EMA guideline and cosmetics law
EU
- The EMA guideline on quality of transdermal patches applies to patches for systemic delivery. Cutaneous patches not meant for systemic absorption are out of its scope. Source sentence
Cutaneous patches (where the active substance is not intended to be systemically absorbed) are out of the scope of this guideline.
3 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 - EU cosmetics law defines a cosmetic product by contact with external body parts and a purpose of cleaning, perfuming, changing appearance, protecting, keeping in good condition or correcting body odour. Source sentence
‘cosmetic product’ means any substance or mixture intended to be placed in contact with the external parts of the human body ... with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours
4 Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk - A substance intended to enter the body, for example by ingestion or implant, is not a cosmetic product under the same article. Source sentence
a substance or mixture intended to be ingested, inhaled, injected or implanted into the human body shall not be considered to be a cosmetic product
4 Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk
United Kingdom: the borderline between cosmetic and medicine
UK
- In Great Britain a product that fits both the cosmetic definition and the medicinal definition is classified as a medicinal product. (reported by MHRA, read through a search summary) Source sentence
MHRA guidance: a product that falls within both the cosmetic and the medicinal product definition is classified as a medicinal product.
5 MHRA, borderline products guidance for Great Britain
European Union: the guideline in force
EU
- The guideline was adopted by the CHMP on 23 October 2014 and came into effect on 17 June 2015. Source sentence
Adopted by CHMP 23 October 2014 ... Date for coming into effect 17 June 2015
3 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
How are peptide patches classified under EU and UK rules?
This guideline addresses new marketing authorisation applications ... for transdermal patches for systemic delivery.3 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/20144 Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk In Great Britain the medicinal definition wins where a product also fits the cosmetic one. (reported by MHRA, read through a search summary) Source sentence
MHRA guidance: both definitions apply, so the product is classified as a medicinal product.5 MHRA, borderline products guidance for Great Britain
Published examples with IDs
Analytical only (no biological model)Journal of controlled release : official journal of the Controlled Release Society 2025
Classification, nomenclature and more than twenty critical quality attributes
- Design
- White paper by international stakeholders on regulatory science of microneedle product forms
- Molecule
- Microneedle product forms not established
Analytical only (no biological model)The Annals of pharmacotherapy 2026
Count of patch products, listed ingredients and posted certificates of analysis
- Design
- Review of patch dietary supplement products sold as natural GLP-1 products
- Molecule
- Supplement patch products not established
- n
- 25
Sources
- 1J Control Release 2025 accessed 11 Nov 2026
- 2PubMed search for transdermal patch without microneedles, 11 November 2026 accessed 11 Nov 2026
- 3EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 accessed 11 Nov 2026
- 4Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk accessed 11 Nov 2026
- 5MHRA, borderline products guidance for Great Britain accessed 11 Nov 2026
- 6Ann Pharmacother 2026 accessed 11 Nov 2026
About this page
Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
Reviewed by the Peptency editorial process. Version 1, edited 11 November 2026, 6 sources.
Cite this page: Peptency Academy. Regulatory status of peptide patches in the US, EU and UK. Version 1./eu/academy/guides/peptide-patch-regulatory-status-us-eu-uk/